Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Fineline Cube Jun 17, 2026
Company Deals

Servier Group Partners with n-Lorem Foundation to Develop ASO Therapies for Rare Neurodevelopmental Disorders

Fineline Cube Jun 17, 2026
Company Deals

Shanghai Juncell Therapeutics Files for HKEX Listing with Breakthrough TIL Therapy GC101 for Solid Tumors

Fineline Cube Jun 17, 2026
Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Fineline Cube Jun 17, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Fineline Cube Jun 17, 2026
Company Drug

Biogen Gains FDA Breakthrough Status for Felzartamab in Kidney Transplant Rejection Treatment

Fineline Cube Oct 11, 2024

Biogen Inc. (NASDAQ: BIIB) has secured breakthrough therapy designation (BTD) from the U.S. Food and...

Company

Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand

Fineline Cube Oct 11, 2024

Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...

Legal / IP Policy / Regulatory

China’s NMPA Proposes Rewards for Internal Whistleblowers in Drug and Medical Device Safety Reporting

Fineline Cube Oct 11, 2024

The National Medical Products Administration (NMPA) of China has issued a draft proposal for the...

Company Drug Medical Device

Sunvozertinib’s Companion Diagnostic Gets NMPA Nod, Fortifying Targeted Therapy Arsenal for NSCLC in China

Fineline Cube Oct 11, 2024

Dizal Pharmaceutical Co., Ltd (SHA: 688192) and Burning Rock Ltd (NASDAQ: BNR, FRA: 6BU0) have...

Company Medical Device

Sino Medical Sciences Secures NMPA Nod for Balloon Guided Catheter to Aid Vascular Procedures

Fineline Cube Oct 10, 2024

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that it has received marketing...

Company Deals

Nona Biosciences Partners with OverT Bio to Develop Next-Generation Cell Therapies for Solid Tumors

Fineline Cube Oct 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...

Company Deals

Bill & Melinda Gates Foundation Invests $17 Million in CanSino Biologics’ Recombinant Polio Vaccine

Fineline Cube Oct 10, 2024

The Bill & Melinda Gates Foundation has committed USD 17 million to support the development...

Company Drug

InnoCare Pharma’s ICP-488 Shows Promising Results in Phase II Psoriasis Study

Fineline Cube Oct 10, 2024

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...

Company Drug

Ascletis Pharma Faces US Import Ban for NASH Drugs ASC41 and ASC43F in Trade Secrets Dispute

Fineline Cube Oct 10, 2024

China’s Ascletis Pharma Inc. (HKG: 1672) is navigating legal proceedings involving its oral thyroid hormone...

Company Deals

Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment

Fineline Cube Oct 10, 2024

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced a capital injection of RMB 220...

Company

Eli Lilly China Appoints Yan Qiong as Vice President of Diabetes Business Unit

Fineline Cube Oct 10, 2024

Effective October 10, 2024, Yan Qiong will join the management team of Eli Lilly (NYSE:...

Policy / Regulatory

Shanghai Releases Local Guidelines to Correct Unhealthy Practices in Pharmaceutical Procurement and Medical Services

Fineline Cube Oct 10, 2024

The Shanghai Municipal Health Commission, along with 13 other bureaus, has issued a local adaptation...

Company Drug

InnoCare Pharma Achieves Positive Phase II Results for TYK2 Inhibitor ICP-488 in Psoriasis Treatment

Fineline Cube Oct 10, 2024

China-based InnoCare Pharma (HKG: 9969; SHA: 688428) has announced positive results from a Phase II...

Company Drug

Ascletis Pharma’s ASC40 Earns FDA Breakthrough Therapy Designation for Fibrotic MASH

Fineline Cube Oct 10, 2024

China-based Ascletis Pharma Inc. (HKG: 1672) has announced that ASC40 (denifanstat), a fatty acid synthase...

Company Deals

HitGen Inc. Partners with Ablink Biotech to Develop Antibody-Oligonucleotide Conjugates

Fineline Cube Oct 10, 2024

China-based HitGen Inc. (SHA: 688222) has entered into a partnership with compatriot firm Ablink Biotech...

Company Drug

Sichuan Biokin’s BL-B01D1 Earns Breakthrough Therapy Designation for Esophageal Cancer from China’s CDE

Fineline Cube Oct 10, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that its bispecific antibody drug conjugate...

Company Drug

Merck’s Keytruda Meets Primary Endpoint in Phase III Study for Head and Neck Cancer

Fineline Cube Oct 10, 2024

US pharmaceutical giant Merck & Co., Inc. (MRK, NYSE: MRK) has announced that the Phase...

Company Drug

Boehringer Ingelheim’s Survodutide Earns FDA Breakthrough Therapy Designation for MASH Treatment

Fineline Cube Oct 10, 2024

German pharmaceutical company Boehringer Ingelheim has received breakthrough therapy designation (BTD) from the US Food...

Company

Eli Lilly Appoints Thomas J. Fuchs as First Chief AI Officer to Lead AI Initiatives

Fineline Cube Oct 10, 2024

Eli Lilly and Company (NYSE: LLY) has announced the appointment of Thomas J. Fuchs, Dr.sc.,...

Company Deals

Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange

Fineline Cube Oct 9, 2024

China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem...

Posts pagination

1 … 306 307 308 … 685

Recent updates

  • Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders
  • Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy
  • WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement
  • Hengrui Pharmaceuticals Receives NMPA Clinical Approvals for Two Novel Anti-Tumor Candidates SHR-6914 and HRS-7525, Addressing Unmet Needs in Prostate Cancer and Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s 13-Valent Pneumococcal Vaccine Weuphoria Meets All Endpoints in Indonesian Phase III Trial

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Achieves First-in-Human Milestone in Phase I Trial for CNS Disorders

Company Drug

Hengrui Pharmaceuticals Expands Dalpiciclib Label with NMPA Approval for Early Breast Cancer Adjuvant Therapy

Company Deals

WuXi XDC Partners with BioDlink International for Monoclonal Antibody Intermediate Manufacturing in RMB 190 Million CRDMO Agreement

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.